High throughput diagnosis can improve the efficiency of cancer diagnosis

Recently, Baylor Medical College, MIT and Harvard University have developed a single needle biopsy technology for cancer diagnosis Based on this technology, researchers can get a deeper understanding of cancer biology, which is helpful for the development of new therapies This new method combines the advantages of genomics and proteomics: single needle core biopsies from patients' tumors were used to analyze tumor genetic material (genomics) and deep protein and phosphoprotein characterization (proteomics) To test the new technology, the researchers evaluated the feasibility of protein genome analysis before and 48 to 72 hours after erbB2 chemotherapy through a preliminary study They hope to evaluate the ability of ERBB2 antibody to inhibit drug targets to gain insights into the differences in results after treatment For the first time, the researchers were able to detect a significant reduction in ERBB2 protein phosphorylation after treatment in patients who responded to the treatment For unresponsive patients, the researchers did not find a decrease in the protein In the patients who did not respond to the treatment, in-depth data analysis shows that there are many mechanisms of drug resistance for erbB2, which can be solved by the actual treatment of patients The measurement of microtechnology provides a large amount of data from tumor and reveals the internal mechanism of various factors driving tumor response, including factors from tumor immune microenvironment This test proves that these technologies are expected to be used in the future development of precision medicine.